May. 5 at 8:38 PM
$JAZZ
🚨🚨🚨🚨
Strong return to profitability: Net income of
$293.1 million for Q1 2026 versus a
$92.5 million loss a year earlier, supported by higher revenues and a sizable one-time gain on sale of a rare pediatric disease priority review voucher.
Robust top-line growth across key franchises: Total revenues increased to
$1,068.9 million from
$897.8 million, with Xywav at
$408.2 million, Epidiolex/Epidyolex at
$249.8 million, and oncology products at
$333.4 million.
Healthy cash generation and liquidity: Net cash provided by operating activities was
$408.2 million, lifting cash and cash equivalents to
$1,844.3 million and total cash plus investments to
$2,874.3 million.
